Stock Research: Aquestive Therapeutics

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Aquestive Therapeutics

NasdaqGM:AQST US03843E1047
18
  • Value
    41
  • Growth
    23
  • Safety
    Safety
    35
  • Combined
    4
  • Sentiment
    57
  • 360° View
    360° View
    18
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Aquestive Therapeutics, Inc. is a pharmaceutical company developing orally administered and topical gel products. It operates in the pharmaceutical industry with products like Anaphylm, AQST-108, Libervant, Suboxone, and Emylif, and commercializes its products in the United States and globally through licensees. In the last fiscal year, the company had a market cap of $403 million, profits of $40 million, revenue of $58 million, and 142 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 18 (better than 18% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aquestive Therapeutics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Aquestive Therapeutics. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 35, which means that the share price of Aquestive Therapeutics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 23, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 23% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 41 which means that the company has a riskier financing structure than 59% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
35 49 51 73
Growth
23 31 99 13
Safety
Safety
41 69 40 29
Sentiment
57 50 73 70
360° View
360° View
18 44 93 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
83 85 88 61
Opinions Change
73 50 50 94
Pro Holdings
n/a 49 83 55
Market Pulse
25 21 11 8
Sentiment
57 50 73 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
35 49 51 73
Growth
23 31 99 13
Safety Safety
41 69 40 29
Combined
4 51 83 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
42 42 42 42
Price vs. Earnings (P/E)
9 15 33 62
Price vs. Book (P/B)
89 93 89 92
Dividend Yield
1 1 1 1
Value
35 49 51 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
91 1 55 49
Profit Growth
18 4 91 33
Capital Growth
15 91 81 13
Stock Returns
33 75 95 41
Growth
23 31 99 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
62 74 46 38
Refinancing
41 65 49 43
Liquidity
29 29 31 34
Safety Safety
41 69 40 29

Similar Stocks

Discover high‑ranked alternatives to Aquestive Therapeutics and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.